US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

321.39

+12.203.95%

Volume:269.23K

Turnover:85.40M

Market Cap:38.09B

PE:-193.33

High:323.20

Open:311.10

Low:306.73

Close:309.19

52wk High:355.30

52wk Low:170.99

Shares:118.51M

Float Shares:75.99M

Volume Ratio:1.43

T/O Rate:0.35%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6624

EPS(LYR):-6.1240

ROE:-4.98%

ROA:-1.06%

PB:10.10

PE(LYR):-52.48

Loading ...

Overview Company News Filings

BeOne Medicines AG expected to post earnings of 78 cents a share - Earnings Preview

How Positive Phase 3 Lung Cancer Results at BeOne Medicines (ONC) Have Changed Its Investment Story

Simply Wall St.

BeOne Medicines Advances Phase 3 Study for CLL/SLL Treatment

BeOne Medicines’ Tislelizumab Study: A Potential Game-Changer for MSI-H/dMMR Tumors

China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)

China's Stock Market Set to Get a Boost From Five-Year Plan -- Market Talk

Press Release: BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6

Beone Medicines : Morgan Stanley Raises Target Price to $383.00 From $350.00

THOMSON REUTERS

What's Going On With Summit Therapeutics Stock On Monday?

Benzinga_recent_news

A Look at BeOne Medicines (ONC) Valuation After Breakthrough Therapy Status for Sonrotoclax

Simply Wall St.

What BeOne Medicines (ONC)'s Breakthrough Therapy Designation for Sonrotoclax Means For Shareholders

Simply Wall St.

百济神州(06160)英文股份简称将变更为“BEONE MEDICINES”

Transforming Over Eight Years in "Patient Capital": Guangdong International Investment Holds Investments in Multiple Star Projects like BEIGENE and XPeng

Hong Kong Stock Market Preview | Spot Silver Prices Surge Dramatically, BEIGENE's Sotorasib Receives Breakthrough Therapy Designation

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Trump Softens China Rhetoric

MT Newswires Live

BeOne Says Lymphoma Therapy Granted FDA Breakthrough Designation

MT Newswires Live

BeOne Medicines’ sonrotoclax granted Breakthrough Therapy Designation by FDA

Bernstein Remains a Hold on BeOne Medicines (ONC)

Beone Medicines : Bernstein Raises Target Price to $362 From $259

THOMSON REUTERS

RBC Capital Remains a Buy on BeOne Medicines (ONC)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ONC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":321.39,"timestamp":1762376400000,"preClose":309.19,"halted":0,"volume":269232,"delay":0,"floatShares":75991800,"shares":118513677,"eps":-1.662384,"marketStatus":"Pre-Mkt","change":12.2,"latestTime":"11-06 05:15:47 EST","open":311.1,"high":323.2,"low":306.73,"amount":85399835.78208001,"amplitude":0.053268,"askPrice":327.3,"askSize":15,"bidPrice":310,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-1.662384,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1762439400000},"marketStatusCode":1,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":321.39,"postHourTrading":{"tag":"盘后","latestPrice":321.39,"preClose":321.39,"latestTime":"19:58 EST","volume":2962,"amount":952087.7,"timestamp":1762390711502},"volumeRatio":1.4337302298478352,"impliedVol":0.5497,"impliedVolPercentile":0.9387},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75991800,"roa":"-1.06%","roe":"-4.98%","lyrEps":-6.124009,"volumeRatio":1.4337302298478352,"shares":118513677,"dividePrice":0,"high":323.2,"amplitude":0.053268,"preClose":309.19,"low":306.73,"week52Low":170.99,"pbRate":"10.10","psRate":"8.35","week52High":355.3,"institutionHeld":0,"latestPrice":321.39,"committee":0.333333,"eps":-1.662384,"divideRate":0,"volume":269232,"delay":0,"ttmEps":-1.662384,"open":311.1,"prevYearClose":184.71,"prevWeekClose":310.48,"prevMonthClose":310.48,"prevQuarterClose":340.7,"fiveDayClose":314.85,"twentyDayClose":351.09,"sixtyDayClose":288.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-11-06","symbol":"ONC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/09","expectedEps":0.72,"defaultRemindTime":1762462800000,"name":null,"time":"Post Market","dateTimestamp":1762405200000,"actualEps":null},{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"Pre-Market","dateTimestamp":1756526400000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.6667,"hold":0.0417,"sell":0.0417,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":24,"updateTime":1758171600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-11-04","current":-193.330783,"percent":0.124654,"low":-217.585346,"twenty":-89.138637,"median":-41.903376,"eighty":-24.138511,"high":-19.234246,"avg":-69.696555,"sd":62.454916,"marketCap":34333182904},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-08-01","current":-91.060669,"twenty":-60.626235,"median":-39.865155,"eighty":-23.250607,"marketCap":35729110635},{"date":"2025-08-08","current":-184.757225,"twenty":-63.824658,"median":-40.051934,"eighty":-23.50984,"marketCap":32820458238},{"date":"2025-08-15","current":-191.818248,"twenty":-64.911375,"median":-40.112152,"eighty":-23.522344,"marketCap":34074785315},{"date":"2025-08-22","current":-194.469228,"twenty":-72.041871,"median":-40.222554,"eighty":-23.535152,"marketCap":34545708113},{"date":"2025-08-29","current":-184.552827,"twenty":-72.8475,"median":-40.343171,"eighty":-23.581122,"marketCap":32784148770},{"date":"2025-09-05","current":-197.417514,"twenty":-73.864189,"median":-40.425269,"eighty":-23.723244,"marketCap":35069444682},{"date":"2025-09-12","current":-208.147892,"twenty":-74.224679,"median":-40.801852,"eighty":-23.82061,"marketCap":36975599617},{"date":"2025-09-19","current":-212.503459,"twenty":-75.66857,"median":-40.932054,"eighty":-23.865007,"marketCap":37749326897},{"date":"2025-09-26","current":-203.715512,"twenty":-76.587723,"median":-41.008162,"eighty":-23.928977,"marketCap":36188227257},{"date":"2025-10-03","current":-213.916471,"twenty":-77.910534,"median":-41.112345,"eighty":-23.950329,"marketCap":38000335866},{"date":"2025-10-10","current":-208.109485,"twenty":-81.639564,"median":-41.598105,"eighty":-24.044918,"marketCap":36968777077},{"date":"2025-10-17","current":-197.090466,"twenty":-85.2662,"median":-41.668284,"eighty":-24.084563,"marketCap":35011347487},{"date":"2025-10-24","current":-192.138725,"twenty":-87.584871,"median":-41.753651,"eighty":-24.09529,"marketCap":34131715179},{"date":"2025-10-31","current":-191.016991,"twenty":-89.061223,"median":-41.811067,"eighty":-24.120226,"marketCap":33932449287},{"date":"2025-11-04","current":-193.272853,"twenty":-89.138637,"median":-41.903376,"eighty":-24.138511,"marketCap":34333182904}],"updateTime":1762397388033},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2580339200","title":"BeOne Medicines AG  expected to post earnings of 78 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580339200","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580339200?lang=en_us&edition=fundamental","pubTime":"2025-11-04 16:07","pubTimestamp":1762243625,"startTime":"0","endTime":"0","summary":"BeOne Medicines AG  expected to post earnings of78cents a share - Earnings Preview BeOne Medicines AG ONC.OQ, ONC.O is expected to  show a rise in quarterly revenue when it reports  results on Novembe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG0O5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","BK4526","BK4585","BK4139"],"gpt_icon":0},{"id":"2578600267","title":"How Positive Phase 3 Lung Cancer Results at BeOne Medicines (ONC) Have Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2578600267","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578600267?lang=en_us&edition=fundamental","pubTime":"2025-10-28 08:28","pubTimestamp":1761611329,"startTime":"0","endTime":"0","summary":"At the European Society of Medical Oncology (ESMO) 2025 Congress in Berlin, BeOne Medicines announced new data from two pivotal Phase 3 trials of its PD-1 inhibitor TEVIMBRA, showing enduring efficacy across multiple lung cancer subtypes, and unveiled the first clinical results of its investigational HPK1 inhibitor in advanced solid tumors.\nAn especially significant outcome was the reported overall survival benefit of TEVIMBRA plus chemotherapy for squamous non-small cell lung cancer...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/how-positive-phase-3-lung-cancer-results-at-beone-medicines","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/how-positive-phase-3-lung-cancer-results-at-beone-medicines","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONC","BK4139","MDCO","BK4526","BK4585"],"gpt_icon":0},{"id":"2578704866","title":"BeOne Medicines Advances Phase 3 Study for CLL/SLL Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2578704866","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578704866?lang=en_us&edition=fundamental","pubTime":"2025-10-28 07:39","pubTimestamp":1761608368,"startTime":"0","endTime":"0","summary":"BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is currently conducting a Phase 3 study titled ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-phase-3-study-for-cll-sll-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-phase-3-study-for-cll-sll-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4526","MDCO","ONC","BK4585","BK4139"],"gpt_icon":0},{"id":"2578629319","title":"BeOne Medicines’ Tislelizumab Study: A Potential Game-Changer for MSI-H/dMMR Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2578629319","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578629319?lang=en_us&edition=fundamental","pubTime":"2025-10-28 00:51","pubTimestamp":1761583878,"startTime":"0","endTime":"0","summary":"BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. Study Overview: BeOne Medicines (ONC) is conducting a Phase 2 study t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-tislelizumab-study-a-potential-game-changer-for-msi-h-dmmr-tumors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-tislelizumab-study-a-potential-game-changer-for-msi-h-dmmr-tumors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065169927.USD","BK4588","LU2065171402.SGD","MDCO","LU2322448957.HKD","LU1974910355.USD","ONC","IE0034235188.USD","LU2125909916.SGD","LU2473716301.USD","LU0950375773.USD","BK4020","LU2106854487.HKD","LU1992135399.USD","LU1992135472.HKD","BK4526","IE00B775SV38.USD","LU0823417737.USD","LU2065170008.USD","IE00B3S45H60.SGD","LU2023250843.SGD","LU1917777945.USD","LU2272731600.USD","LU2506952170.USD","MSI","LU2272731865.HKD","LU2506951875.HKD","LU2506952097.USD","LU2065171311.SGD","LU0823417653.USD","BK4139","BK4585","LU2247934214.USD","LU1923622291.USD","LU0354030511.USD","LU2272731782.SGD","LU0354030438.USD","LU2322448791.USD","LU2506951958.HKD","LU2023250504.SGD","LU2125909759.SGD"],"gpt_icon":0},{"id":"2578656610","title":"China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)","url":"https://stock-news.laohu8.com/highlight/detail?id=2578656610","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578656610?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:00","pubTimestamp":1761562800,"startTime":"0","endTime":"0","summary":"Designation granted for gotistobart  for the treatment of patients with squamous non-small cell lung cancer , an aggressive subtype of lung cancer. Breakthrough Therapy designation will allow for an expedited development and regulatory review of gotistobart in China. ROCKVILLE, Md., Oct. 27, 2025 /PRNewswire/ -- OncoC4 announced today that China's National Medical Product Administration  has granted Breakthrough Therapy Designation  for gotistobart  for the treatment of patients with squamous non-small cell lung cancer  who have progressed on prior standard immuno-oncology therapies . Gotistobart is a next-generation anti-CTLA-4 antibody candidate which is being jointly developed by BioNTech and OncoC4.Gotistobart is currently being evaluated in a registrational two-stage randomized Phase 3 trial, PRESERVE-003 . The clinical trial assesses the efficacy and safety of gotistobart as monotherapy compared to the standard-of-care chemotherapy  in patients with metastatic sqNSCLC that progre","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2787251/OncoC4_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2787251/OncoC4_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/chinas-nmpa-grants-breakthrough-therapy-designation-for-anti-ctla-4-antibody-candidate-gotistobart-bnt316onc-392-302595190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","ONC","BK4585","BK4526","LU2487616109.SGD","BK4139","L","LU0210528500.USD","LU0053666078.USD","BK4588"],"gpt_icon":0},{"id":"2578615704","title":"China's Stock Market Set to Get a Boost From Five-Year Plan -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2578615704","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578615704?lang=en_us&edition=fundamental","pubTime":"2025-10-27 17:09","pubTimestamp":1761556140,"startTime":"0","endTime":"0","summary":"0909 GMT - China's imminent 15th Five-Year Plan is set to give the country's stock market a boost, HSBC analysts say in a research report. The A-share market has logged average returns of 16.5% in the year after the release of Beijing's Five-Year Plan, the analysts say. \"Strategically important industries explicitly mentioned in the plan could have an excess return of 17.5% on average,\" they add. HSBC highlights three likely investment themes: tech innovation and self-sufficiency, consumption growth, and the green transition. HSBC favors Naura Technology, Kingsoft Office and BeOne for tech innovation on Beijing's IT localization initiative, Yili for consumption, and EVE Energy for the green transition on expected price increases in energy storage system batteries. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","ONC","300014","LU0516423174.USD","HSHD.SI","BK0155","LU0128525689.USD","LU0348735423.USD","LU1961090484.USD","LU1255011170.USD","LU0823437842.USD","LU1997245177.USD","SG9999003461.SGD","LU0540923850.HKD","BK1610","EVS.SI","LU1039395188.USD","LU2328871848.SGD","BK0224","03143","BK0125","BK4588","LU2148510915.USD","BK4526","LU1481107354.HKD","LU2495084118.USD","BK0077","HSBC","LU1064131003.USD","BK0251","LU0634319403.HKD","00005","SGXZ81163826.USD","HSBA.UK","LU0417516738.SGD","BK0188","LU2399975544.HKD","LU0516422440.USD","BK4585","BK0132","LU1720050803.USD","SGXZ49509284.SGD","BK4207","BK1601","LU0052756011.USD","BK4139","LU2236285917.USD","LU0516423091.SGD","BK4521","002371"],"gpt_icon":0},{"id":"2577350836","title":"Press Release: BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6","url":"https://stock-news.laohu8.com/highlight/detail?id=2577350836","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577350836?lang=en_us&edition=fundamental","pubTime":"2025-10-22 18:05","pubTimestamp":1761127500,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd. , a global oncology company, will report its third quarter 2025 financial results on Thursday, November 6, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's plans, commitments, aspirations and goals related to BeOne's medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled \"Risk Factors\" in BeOne's most recent periodic report filed with the U.S. Securities and Exchange Commission  as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC. All in","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","BK4139","MDCO","BK4526","BK4585"],"gpt_icon":0},{"id":"2576868848","title":"Beone Medicines : Morgan Stanley  Raises Target Price to $383.00 From $350.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2576868848","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576868848?lang=en_us&edition=fundamental","pubTime":"2025-10-20 22:11","pubTimestamp":1760969491,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nAZN4ON1FN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONC","BK4139","BK4526","BK4585"],"gpt_icon":0},{"id":"2576786358","title":"What's Going On With Summit Therapeutics Stock On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2576786358","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576786358?lang=en_us&edition=fundamental","pubTime":"2025-10-20 22:05","pubTimestamp":1760969100,"startTime":"0","endTime":"0","summary":"Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/20/Summit-Therapeutics.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/20/Summit-Therapeutics.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/10/48303693/whats-going-on-with-summit-therapeutics-stock-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48303693/whats-going-on-with-summit-therapeutics-stock-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU1571399168.USD","BK4516","IE00BLSP4239.USD","LU0070302665.USD","SG9999014542.SGD","BK4534","LU1066051498.USD","LU2361044865.SGD","BK4139","LU1929549753.HKD","LU0456854461.SGD","BK4539","LU0965508806.USD","ONC","SGXZ57979304.SGD","LU2361045086.USD","LU0265550359.USD","IE00BFTCPJ56.SGD","IE000M9KFDE8.USD","LU1066053197.SGD","BK4211","LU1093756168.USD","LU0058720904.USD","LU2361044949.HKD","IE00BJT1NW94.SGD","LENZ","ORR","LU2023250504.SGD","LU0006306889.USD","LU0965509010.AUD","LU1037948897.HKD","SMMF","CRC","BK4533","LU1989772840.SGD","LU1093756325.SGD","LU1989772923.USD","LU1934455277.USD","LU0289739699.SGD","LU0208291251.USD","LU2468319806.SGD","LU1057294990.SGD","SMMT","LU0861579265.USD","SG9999001176.USD","MRK","LU0234572021.USD","LU1989771016.USD","SG9999001440.SGD","LU1974910355.USD"],"gpt_icon":0},{"id":"2576886053","title":"A Look at BeOne Medicines (ONC) Valuation After Breakthrough Therapy Status for Sonrotoclax","url":"https://stock-news.laohu8.com/highlight/detail?id=2576886053","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576886053?lang=en_us&edition=fundamental","pubTime":"2025-10-20 08:19","pubTimestamp":1760919594,"startTime":"0","endTime":"0","summary":"BeOne Medicines has caught investors’ attention after the company announced that the FDA granted Breakthrough Therapy Designation to its investigational drug, sonrotoclax, for relapsed or refractory mantle cell lymphoma. Participation in Project Orbis could also help accelerate the therapy’s review worldwide.\nSee our latest analysis for BeOne Medicines.\nMomentum has clearly been building for BeOne Medicines, with the FDA news helping to extend an already impressive run. The stock has surged...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/a-look-at-beone-medicines-onc-valuation-after-breakthrough-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/a-look-at-beone-medicines-onc-valuation-after-breakthrough-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4526","MDCO","BK4139","ONC","BK4585"],"gpt_icon":0},{"id":"2576099438","title":"What BeOne Medicines (ONC)'s Breakthrough Therapy Designation for Sonrotoclax Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2576099438","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576099438?lang=en_us&edition=fundamental","pubTime":"2025-10-18 10:24","pubTimestamp":1760754243,"startTime":"0","endTime":"0","summary":"On October 13, 2025, BeOne Medicines announced that the FDA granted Breakthrough Therapy Designation for its investigational BCL2 inhibitor, sonrotoclax, in relapsed or refractory mantle cell lymphoma, alongside acceptance into Project Orbis for concurrent global regulatory review.\nThis marks an important regulatory milestone that could potentially accelerate sonrotoclax’s path to market for patients with limited treatment options in this challenging cancer type.\nWe'll examine how the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/what-beone-medicines-oncs-breakthrough-therapy-designation-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/what-beone-medicines-oncs-breakthrough-therapy-designation-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ONC","MDCO","BK4526","BK4585"],"gpt_icon":0},{"id":"1175139714","title":"百济神州(06160)英文股份简称将变更为“BEONE MEDICINES”","url":"https://stock-news.laohu8.com/highlight/detail?id=1175139714","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175139714?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:34","pubTimestamp":1760708068,"startTime":"0","endTime":"0","summary":"百济神州(06160)宣布，在其英文名称变更完成后，公司在香港联交所的英文股份简称将由“BEIGENE”改为“BEONE MEDICINES”，该变更将于2025年10月22日星期三上午九时正（香港时间）生效。与此同时，公司在香港联交所的中文股份简称仍然保持为“百济神州”。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","LU1969619763.USD","LU0588546209.SGD","LU1719994722.HKD","06160","688235","BK1500","BK1588","BK4526","BK1161","BK1583","LU2328871848.SGD","LU1251922891.USD","BK4585","LU1770034418.SGD","BK0239","LU1303224171.USD","BK4139","ONC"],"gpt_icon":0},{"id":"1153942654","title":"Transforming Over Eight Years in \"Patient Capital\": Guangdong International Investment Holds Investments in Multiple Star Projects like BEIGENE and XPeng","url":"https://stock-news.laohu8.com/highlight/detail?id=1153942654","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153942654?lang=en_us&edition=fundamental","pubTime":"2025-10-16 17:20","pubTimestamp":1760606456,"startTime":"0","endTime":"0","summary":"Special Feature: 2025 Sustainable Global Leadership Conference & First Green Industry and Sustainable Consumption Expo From October 16 to 18, the 2025 Sustainable Global Leadership Conference is...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1575","LU0588546209.SGD","09868","BK1161","BK4505","BK1583","06160","BK1119","BK4526","BK4585","LU2328871848.SGD","LU1969619763.USD","LU0307460666.USD","LU1719994722.HKD","BK1588","BK4555","XPEV","BK4099","BK4551","BK4139","BK1587","LU1251922891.USD","BK1610","BK1539","161027","BK0239","EVS.SI","LU1770034418.SGD","ONC","688235","LU0593848301.USD","LU1303224171.USD","BK1500"],"gpt_icon":1},{"id":"1177962881","title":"Hong Kong Stock Market Preview | Spot Silver Prices Surge Dramatically, BEIGENE's Sotorasib Receives Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1177962881","media":"Stock News","labels":["productRelease","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177962881?lang=en_us&edition=fundamental","pubTime":"2025-10-14 07:24","pubTimestamp":1760397896,"startTime":"0","endTime":"0","summary":"**Today's Headlines** Rare Short Squeeze Unfolds as Spot Silver Prices Surge Dramatically In the early hours of October 14th Beijing time, the silver market experienced a rare short squeeze not seen...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","SG9999004220.SGD","IE00BZ08YT58.USD","IE0008368742.USD","BK1184","BK1163","BK4526","LU1960683339.HKD","LU0140636845.USD","00815","BK1515","LU1226287529.USD","LU1226288170.HKD","LU1951186391.HKD","LU0307460666.USD","IE00B031HY20.USD","00666","LU0315179316.USD","BK1234","LU1226288253.USD","01093","02577","LU0067412154.USD","LU1993786604.SGD","LU0572940350.SGD","IE0008369823.USD","BK1550","LU1303224171.USD","BK1116","LU0501845795.SGD","LU0880133367.SGD","LU1008478684.HKD","LU1719994722.HKD","LU1152091168.USD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","BK1592","LU1807302812.USD","LU2328871848.SGD","LU0264606111.USD","688235","LU1226287875.USD","BK4139","LU1226287792.SGD","LU0314109678.HKD","06160","LU2039709279.SGD","LU1813983027.USD","BK1161","LU0572939691.SGD","BK0239","BK1500","BK1521","BK1588","IE00B5MMRT66.SGD","LU1152091754.HKD","BK1583","01336","LU1770034418.SGD","LU1251922891.USD","BK1584","LU0588546209.SGD","LU1969619763.USD","LU1328277881.USD","BK1191","LU0072913022.USD","IE00BZ08YR35.GBP","ONC","BK4585"],"gpt_icon":0},{"id":"2575401894","title":"Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Trump Softens China Rhetoric","url":"https://stock-news.laohu8.com/highlight/detail?id=2575401894","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575401894?lang=en_us&edition=fundamental","pubTime":"2025-10-13 21:01","pubTimestamp":1760360477,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 1.1% and the actively traded Invesco QQQ Trust (QQQ) was 1.6% higher in recent Monday premarket activity after President Trump","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"80ffe81dc25e6bffb23d89c5090461a6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RTH.AU","IYJ","XLF","USO","EEM","XLP","IBB","VIS","IYH","XLV","IVV","BITO","IGM","IGV","IWM","STLA","CAT.AU","IYW","XRT","VHT.AU","IPK","EETH","VDC","XLI","XSD","BETH","UNG","VHT","XLY",".IXIC","SPY","XLK","EQR","PMR","FAS","MCHP","URG","SPY.AU","FAZ","SOXX","ONC","IYK","QQQ","RTH","XLE","CAT","IYE","BX"],"gpt_icon":1},{"id":"2575705634","title":"BeOne Says Lymphoma Therapy Granted FDA Breakthrough Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2575705634","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575705634?lang=en_us&edition=fundamental","pubTime":"2025-10-13 18:50","pubTimestamp":1760352636,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced Monday that the US Food and Drug Administration has granted breakthrough therapy designation for sonrotoclax, its investigational therapy for the treatment of adult pat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONC","BK4585","BK4139","BK4526"],"gpt_icon":0},{"id":"2575472749","title":"BeOne Medicines’ sonrotoclax granted Breakthrough Therapy Designation by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2575472749","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575472749?lang=en_us&edition=fundamental","pubTime":"2025-10-13 18:10","pubTimestamp":1760350246,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has granted Breakthrough Therapy Designation for sonrotoclax, a next-generation and potentially b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-sonrotoclax-granted-breakthrough-therapy-designation-by-fda-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-sonrotoclax-granted-breakthrough-therapy-designation-by-fda-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4526","BK4585","BK4139","MDCO","ONC"],"gpt_icon":0},{"id":"2574164383","title":"Bernstein Remains a Hold on BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2574164383","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574164383?lang=en_us&edition=fundamental","pubTime":"2025-10-09 23:35","pubTimestamp":1760024120,"startTime":"0","endTime":"0","summary":"In a report released today, Rebecca Liang from Bernstein maintained a Hold rating on BeOne Medicines, with a price target of $362.00. The company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-hold-on-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-hold-on-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","BK4526","MDCO","BK4139","BK4585"],"gpt_icon":0},{"id":"2574130490","title":"Beone Medicines : Bernstein Raises Target Price to $362 From $259","url":"https://stock-news.laohu8.com/highlight/detail?id=2574130490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574130490?lang=en_us&edition=fundamental","pubTime":"2025-10-09 17:46","pubTimestamp":1760003184,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nFWN3VQ12Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONC","BK4526","688235","BK4585","BK4139","BK0239"],"gpt_icon":0},{"id":"2574831973","title":"RBC Capital Remains a Buy on BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2574831973","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574831973?lang=en_us&edition=fundamental","pubTime":"2025-10-09 00:36","pubTimestamp":1759941361,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev maintained a Buy rating on BeOne Medicines today and set a price target of $374.00. The company’s shares opened...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-beone-medicines-onc-blurbs-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-beone-medicines-onc-blurbs-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","BK4207","ONC","LU0029864427.USD","BK4139","BK4585","LU0128525929.USD","LU0310800379.SGD","LU1267930573.SGD","BK4526","LU0708994859.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":68,"code":"91000000","status":"200"}]}}